MDxHealth SA ADR (MDXH) - Total Assets
Based on the latest financial reports, MDxHealth SA ADR (MDXH) holds total assets worth $154.28 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See MDxHealth SA ADR net assets for net asset value and shareholders' equity analysis.
MDxHealth SA ADR - Total Assets Trend (2004–2024)
This chart illustrates how MDxHealth SA ADR's total assets have evolved over time, based on quarterly financial data.
MDxHealth SA ADR - Asset Composition Analysis
Current Asset Composition (December 2024)
MDxHealth SA ADR's total assets of $154.28 Million consist of 42.5% current assets and 57.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 29.8% |
| Accounts Receivable | $14.53 Million | 9.2% |
| Inventory | $3.87 Million | 2.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $40.59 Million | 25.8% |
| Goodwill | $35.93 Million | 22.8% |
Asset Composition Trend (2004–2024)
This chart illustrates how MDxHealth SA ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see MDXH market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MDxHealth SA ADR's current assets represent 42.5% of total assets in 2024, a decrease from 85.4% in 2004.
- Cash Position: Cash and equivalents constituted 29.8% of total assets in 2024, up from 3.5% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 47.0% of total assets, an increase from 5.0% in 2004.
- Asset Diversification: The largest asset category is intangible assets at 25.8% of total assets.
MDxHealth SA ADR Competitors by Total Assets
Key competitors of MDxHealth SA ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Eurofins-Cerep SA
PA:ALECR
|
France | €84.58 Million |
|
Inoviq Ltd
AU:IIQ
|
Australia | AU$24.52 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.17 Million |
|
Imagion Biosystems Ltd
AU:IBX
|
Australia | AU$932.48K |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
MDxHealth SA ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.14 | 1.54 | 1.77 |
| Quick Ratio | 1.02 | 1.45 | 1.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $7.06 Million | $24.65 Million | $10.07 Million |
MDxHealth SA ADR - Advanced Valuation Insights
This section examines the relationship between MDxHealth SA ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 23.55 |
| Latest Market Cap to Assets Ratio | 0.71 |
| Asset Growth Rate (YoY) | 21.8% |
| Total Assets | $157.33 Million |
| Market Capitalization | $111.46 Million USD |
Valuation Analysis
Below Book Valuation: The market values MDxHealth SA ADR's assets below their book value (0.71x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: MDxHealth SA ADR's assets grew by 21.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for MDxHealth SA ADR (2004–2024)
The table below shows the annual total assets of MDxHealth SA ADR from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $157.33 Million | +21.84% |
| 2023-12-31 | $129.13 Million | +8.39% |
| 2022-12-31 | $119.14 Million | +58.69% |
| 2021-12-31 | $75.07 Million | +135.66% |
| 2020-12-31 | $31.86 Million | -21.59% |
| 2019-12-31 | $40.63 Million | -37.95% |
| 2018-12-31 | $65.48 Million | +11.88% |
| 2017-12-31 | $58.52 Million | -13.59% |
| 2016-12-31 | $67.72 Million | +17.28% |
| 2015-12-31 | $57.74 Million | +86.55% |
| 2014-12-31 | $30.95 Million | +5.34% |
| 2013-12-31 | $29.38 Million | +46.91% |
| 2012-12-31 | $20.00 Million | +5.04% |
| 2011-12-31 | $19.04 Million | -0.70% |
| 2010-12-31 | $19.18 Million | -45.93% |
| 2009-12-31 | $35.46 Million | -34.77% |
| 2008-12-31 | $54.36 Million | -6.56% |
| 2007-12-31 | $58.18 Million | +19.87% |
| 2006-12-31 | $48.54 Million | +188.76% |
| 2005-12-31 | $16.81 Million | +91.80% |
| 2004-12-31 | $8.76 Million | -- |
About MDxHealth SA ADR
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the… Read more